As we age, our arteries and blood vessels tend to accumulate plaque, leading to a decreased blood flow and eventually, to a host of cardiovascular problems. But what if there were a way to prevent or even reverse this process? A growing body of evidence suggests that lowering low-density lipoprotein (LDL) cholesterol levels to 1.4 mmol/L or lower could be the key to keeping our arteries healthy and free from clogging.
One way to achieve this target is through the use of statins such as rosuvastatin or atorvastatin, which have been proven to lower LDL levels effectively. However, some individuals have found that these drugs may not be enough to achieve their desired cholesterol levels, leading them to explore additional options, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors like Repatha or Praulen. These drugs have been found to reduce LDL levels by 30-60% for many individuals, and also have the added benefit of reducing levels of lipoprotein (a), another risk factor for cardiovascular disease.
Despite the promising results of Repatha, which has been available for 7 years, some people remain wary of its long-term safety, as the drug is still relatively young. However, many healthy individuals subscribe to the idea that maintaining low LDL levels early in life could significantly reduce the risk of heart attacks and extend one’s lifespan.
For those who are not satisfied with statins or PCSK9 inhibitors, there is now another option in the form of inclisiran, a recently released PCSK9 inhibitor that has the advantage of requiring just one injection every 6 months. Unlike Repatha, inclisiran operates through a different mechanism, making it an attractive choice for some individuals.
The overarching idea behind these interventions is the belief that clogging of arteries and blood vessels is an inevitable part of aging, and that the only variable is the speed and extent of the clogging. By reducing LDL levels and preventing plaque buildup, individuals hope to extend their healthy lifespan and maintain optimal blood flow throughout their bodies.
In conclusion, as we continue to explore new ways to keep our arteries healthy and clog-free, the world of lipid-lowering drugs remains an exciting and ever-evolving field. Whether through statins, PCSK9 inhibitors, or new innovations like inclisiran, individuals are taking a proactive approach to their cardiovascular health and seeking to extend their healthy years. The quest for a clog-free artery is a journey well worth taking.
*Disclaimer: The author of this article is not a medical doctor and this article is not intended to be taken as medical advice. It is always recommended to consult with a qualified healthcare professional before making any decisions about treatment or medication.